LABELS · 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

CLIGAVYX

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-24
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )

Full extracted label fields

application numbers

NDA210063

boxed warning exact

brand names

CLIGAVYX

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e20d8ca3-8837-4003-8b01-1ebec342062a

generic names

FULVESTRANT

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

indications and usage exact

1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )

indications and usage tables exact

is original packager

true

manufacturer names

Avyxa Pharma, LLC

matched search terms

cancer

package ndcs

83831-159-02

product ndcs

83831-159

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAMUSCULAR

rxcuis

727762
2745138

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 578
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endoc
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 0

current approval status

not_reconciled

duplicate text group

dup-ed67f8a740453be8e7e4

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-543de04d65317f1b0244

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

end: 57
end exclusive: true
exact text: is indicated
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 45

qualifier mentions

context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine ther
kind
biomarker
polarity
not_inferred
span
end
198
end exclusive
true
exact text
HER2)-negative advanced breast cancer in pos
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
154
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-pos
kind
stage_or_setting
polarity
not_inferred
span
end
212
end exclusive
true
exact text
advanced breast cancer in postmenopausal wo
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
169
context exact
t previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
321
end exclusive
true
exact text
advanced breast cancer in postmenopausal wo
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
278
context exact
negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
377
end exclusive
true
exact text
previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
220

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 378
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 851
end exclusive: true
exact text: reast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen recep
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 179

current approval status

not_reconciled

duplicate text group

dup-250237d1c141fdc34b94

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-21157cd6cb34eaaab13b

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

end: 420
end exclusive: true
exact text: is indicated
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 408

qualifier mentions

context exact
py CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribocicli
kind
biomarker
polarity
not_inferred
span
end
500
end exclusive
true
exact text
HER2-negative advanced or metastatic breast
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
456
context exact
indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial
kind
stage_or_setting
polarity
not_inferred
span
end
513
end exclusive
true
exact text
advanced or metastatic breast cancer in pos
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
470
context exact
dvanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.
kind
regimen
polarity
not_inferred
span
end
650
end exclusive
true
exact text
in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
531

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 651
end exclusive: true
exact text: Combination Therapy CLIGAVYX is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 379

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1021
end exclusive: true
exact text: ve, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmeno
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 452

current approval status

not_reconciled

duplicate text group

dup-48fa547e6142a292ed8f

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-791e30a286a170fc8310

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

end: 420
end exclusive: true
exact text: is indicated
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 408

qualifier mentions

context exact
HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in wom
kind
biomarker
polarity
not_inferred
span
end
709
end exclusive
true
exact text
HER2-negative advanced or metastatic breast
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
665
context exact
HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disea
kind
stage_or_setting
polarity
not_inferred
span
end
722
end exclusive
true
exact text
advanced or metastatic breast cancer in com
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
679
context exact
ositive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
kind
regimen
polarity
not_inferred
span
end
820
end exclusive
true
exact text
in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
716

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 821
end exclusive: true
exact text: HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 652

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · positive indication candidate

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1280
end exclusive: true
exact text: ression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmen
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 622

current approval status

not_reconciled

duplicate text group

dup-a16d23bd42bdfb88600d

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-5b9add1584ec74419ba8

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

end: 875
end exclusive: true
exact text: is an estrogen receptor antagonist indicated
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 831

qualifier mentions

context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine ther
kind
biomarker
polarity
not_inferred
span
end
1016
end exclusive
true
exact text
HER2)-negative advanced breast cancer in pos
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
972
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1030
end exclusive
true
exact text
advanced breast cancer in postmenopausal wo
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
987
context exact
negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1079
end exclusive
true
exact text
previously treated with endocrine therapy
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1038

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1080
end exclusive: true
exact text: CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 822

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1399
end exclusive: true
exact text: he treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on en
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 881

current approval status

not_reconciled

duplicate text group

dup-e6e064ff38f0f814fdea

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-2a0b89e1aa1561030524

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

Source null

qualifier mentions

context exact
( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1142
end exclusive
true
exact text
advanced breast cancer in postmenopausal wo
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1099

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1199
end exclusive: true
exact text: ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1081

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1597
end exclusive: true
exact text: st cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1000

current approval status

not_reconciled

duplicate text group

dup-3c83a616f694c8ca3a0e

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-0fbbbeac4cf26d3f514f

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

end: 875
end exclusive: true
exact text: is an estrogen receptor antagonist indicated
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 831

qualifier mentions

context exact
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribocicli
kind
biomarker
polarity
not_inferred
span
end
1263
end exclusive
true
exact text
HER2-negative advanced or metastatic breast
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1219
context exact
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial
kind
stage_or_setting
polarity
not_inferred
span
end
1276
end exclusive
true
exact text
advanced or metastatic breast cancer in pos
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1233
context exact
dvanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.
kind
regimen
polarity
not_inferred
span
end
1414
end exclusive
true
exact text
in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1294

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1415
end exclusive: true
exact text: ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1200

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1597
end exclusive: true
exact text: e, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1216

current approval status

not_reconciled

duplicate text group

dup-9afb3fedff5a46c6773a

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-3004c4276543d1f83277

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

end: 875
end exclusive: true
exact text: is an estrogen receptor antagonist indicated
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 831

qualifier mentions

context exact
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in wom
kind
biomarker
polarity
not_inferred
span
end
1479
end exclusive
true
exact text
HER2-negative advanced or metastatic breast
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1435
context exact
( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disea
kind
stage_or_setting
polarity
not_inferred
span
end
1492
end exclusive
true
exact text
advanced or metastatic breast cancer in com
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1449
context exact
ositive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
kind
regimen
polarity
not_inferred
span
end
1590
end exclusive
true
exact text
in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy
label id
29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start
1486

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1591
end exclusive: true
exact text: ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1416

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · unclassified context

application numbers

NDA210063

brand names

CLIGAVYX

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1597
end exclusive: true
exact text: n on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 )
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1392

current approval status

not_reconciled

duplicate text group

dup-f92ddac12dd3da7cbf50

extraction review status

automated_candidate_pending_source_review

generic names

FULVESTRANT

ind-span-edd2bcc9d9e54cdc386d

label id

29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1597
end exclusive: true
exact text: ( 1 )
label id: 29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fde85291414a11e3dce9194ef5c92a78973c0961ad101c39c488087b0c5ed107
start: 1592

source url

https://api.fda.gov/drug/label.json?search=id%3A%2229f2a48e-b9af-486e-bc0c-eab3a1ce0b3c%22

spl effective date

2026-06-24

spl set id

e20d8ca3-8837-4003-8b01-1ebec342062a

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice